Choice Broking maintained an ‘ADD’ rating and a target price of Rs 1,825 on Sun Pharma. At the prevailing price, the target ...

Sun Pharmaceutical's shares fell 5.7% to ₹1,608.30 after a 20% drop in net profit to ₹2,278 crore for Q1 FY26. Despite this, ...

Sun Pharma stock fell as much as 5.78% during trade so far to Rs 1,608 apiece on the NSE. It was trading 3.65% lower at Rs ...

Sun Pharmaceutical Industries reported a 20% decline in net profit for Q1 FY26, but adjusted profits excluding exceptions ...

Sun Pharmaceutical Industries reported a decline of 20 per cent in net profit at Rs. 2,278.63 crore during the first quarter of the current fiscal year, as compared to Rs. 2,835.62 crore during the ...

Healthy double-digit growth in its India business and innovative medicines pipeline boosted its revenue and Ebitda margins ...

Sun Pharmaceutical Industries, announced its release of Leqselvi in the U.S. earlier this week. Leqselvi™ is currently available to health care providers and adults suffering from severe alopecia ...

Sun Pharmaceutical Industries reported a 20% decline in net profit for Q1 FY26, standing at ₹2,279 crore. The fall is ...

India's top drugmaker by revenue Sun Pharma on Monday launched its anti-baldness drug Leqselvi in the U.S., following the ...

Sun Pharma's top management reassures no plans to shift manufacturing to US despite looming tariffs, strong Q1 performance.

The approval of Leqselvi for adults with severe alopecia areata (at least 50% scalp hair loss) was based on positive results from two phase 3 clinical trials: THRIVE-AA1 (ClinicalTrials.gov ...

Rinvoq’s efficacy in alopecia areata is “impressive,” according to Guggenheim analysts, who said the drug could have a ...